top of page

New EU Guidance Clarifies Clinical Evidence Requirements for Orphan IVDs

2 days ago
4 min read

Regulatory Update | In Vitro Diagnostic Medical Devices | November 2026


On 3 November 2026, the Medical Device Coordination Group (MDCG) published MDCG 2026-6: Clinical Evidence for Orphan In Vitro Diagnostic Medical Devices.


The guidance tackles a real challenge under the EU's In Vitro Diagnostic Medical Devices Regulation (IVDR): demonstrating sufficient clinical evidence for tests intended for rare diseases, uncommon conditions, or exceptional clinical circumstances.


Belgium's Federal Agency for Medicines and Health Products (FAMHP), together with France's National Agency for the Safety of Medicines and Health Products (ANSM), played a leading role in developing it through a dedicated MDCG task force. It's an EU-level guidance document rather than a new Belgian national regulation, but it's directly relevant to manufacturers operating in Belgium and across the European market.


Why Was New Guidance Needed?


Under Regulation (EU) 2017/746 (IVDR), manufacturers must demonstrate the scientific validity, analytical performance, and clinical performance of their IVDs. For tests targeting rare diseases or unusual clinical situations, that's hard: a small affected population makes it difficult to obtain clinical specimens, recruit participants for performance studies, and build large datasets before market entry.


MDCG 2026-6 recognises these practical difficulties and explains how clinical evidence requirements can be applied proportionately without compromising patient safety or expected clinical benefit.


What Qualifies as an Orphan IVD?


A device must be specifically intended to test individuals for a disease, condition, or circumstance affecting no more than 12,000 people in the EU per year. In addition, at least one of the following must apply:


  • There are insufficient available alternatives, or

  • The device is expected to provide a clinical benefit compared with available alternatives or the current state of the art


A few important points:


  • The threshold relates to the annual incidence of the condition, not the number of tests performed

  • Manufacturers claiming orphan status must provide a scientific justification, supported by epidemiological information, the intended purpose, and an assessment of available alternatives

  • Orphan status does not provide market exclusivity; more than one CE-marked orphan IVD may exist for the same condition where the criteria are met


How the Guidance Changes the Approach to Clinical Evidence


One of the most significant clarifications: limitations in pre-market clinical performance data may be acceptable where obtaining more evidence before market entry isn't feasible or proportionate within an acceptable timeframe.


But this doesn't remove the manufacturer's responsibility. You must:


  • Evaluate all available evidence

  • Identify its limitations

  • Demonstrate the evidence is sufficient to establish an acceptable benefit-risk profile and an expected clinical benefit


Non-clinical evidence can also contribute to the performance evaluation, for example:


  • Scientific literature

  • Analytical performance data from similar assays

  • Disease registries

  • Computer modelling

  • Data from other relevant sources


The relevance and reliability of each source must be justified for the specific device and intended purpose.


Greater Emphasis on Post-Market Evidence


The guidance puts particular weight on post-market surveillance (PMS) and post-market performance follow-up (PMPF). Where limitations in pre-market data have been accepted, manufacturers must set up structured plans to generate additional evidence after market placement. These plans should identify:


Element

What It Covers

Limitations

The pre-market data gaps still to be addressed

Information needed

What's required to evaluate clinical performance and safety

Methods

How the data will be collected

Timelines

Realistic milestones and expected availability of patient specimens

Assessment

How findings will feed into the ongoing performance evaluation


The role of notified bodies: depending on the circumstances, a notified body may set specific conditions for certification, including defined post-market activities and deadlines for generating additional evidence. Failing to meet those conditions may ultimately affect the validity of the certificate.


What Manufacturers Should Consider


If you develop or commercialise diagnostic tests for rare conditions, review your regulatory and evidence strategy against the new guidance:

1. Check orphan IVD eligibility: Assess whether your device meets the criteria, and make sure the justification is well documented.


2. Review your performance evaluation report. Check its completeness and whether existing non-clinical and clinical data support the intended purpose.


3. Identify remaining evidence gaps. Be explicit about what's missing and why.


4. Build a realistic post-market evidence plan. Set achievable timelines, methods, and milestones.


5. Engage early. Early discussion with notified bodies and, where appropriate, relevant expert panels can clarify evidence expectations before conformity assessment progresses.


Remember: the guidance doesn't create an automatic route to CE marking, and it doesn't exempt orphan IVDs from IVDR requirements.


ARQon Insight


MDCG 2026-6 brings welcome clarity to an area of IVD regulation where evidence generation is especially challenging.


For manufacturers, the key question isn't simply "Does our test qualify as an orphan IVD?" It's whether the available evidence, the justification for any limitations, and the proposed post-market activities together demonstrate acceptable safety, performance, and clinical benefit.


Companies planning to enter or expand in Europe should build these principles into product development and regulatory planning early.


Key Takeaway


MDCG 2026-6 introduces a clearer, more proportionate approach to clinical evidence for orphan IVDs recognising the practical challenges of generating data for rare conditions while maintaining the safety and performance standards of the IVDR.


Effective regulatory planning means combining a strong scientific justification, a well-supported performance evaluation, and a structured post-market evidence strategy.


For orphan IVDs, a smaller dataset can be acceptable but only with a stronger plan.


How ARQon Can Support You


At ARQon, we support healthcare companies navigating evolving international requirements with:


  • Regulatory intelligence

  • Market-entry strategy

  • Regulatory pathway assessment

  • Compliance planning


Stay Ahead. Stay Compliant. Stay Informed. With ARQon Regulatory Intelligence.


Official Sources


Regulatory note: MDCG guidance supports the interpretation and practical application of the IVDR. It is not legally binding and does not amend Regulation (EU) 2017/746.

Comments


bottom of page